Continuous infusion fluorouracil in the management of advanced breast cancer: A phase II study

Diana Crivellari, Maria Donatella Magri, Angela Buonadonna, Davide Lombardi, Concetta Paolello, Marcello De Cicco, Dario Fantin, Andrea Veronesi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aims and background: The evaluation of unconventional schedules of well- known drugs represents a promising avenue in the search for new regimens with a better therapeutic index in metastatic breast cancer. In particular, protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has yielded interesting results in gastrointestinal malignancies and in breast cancer. Methods: From March 1996 30 consecutive patients with heavily pretreated breast cancer were treated with PCI 5-FU at a daily dose of 250 mg/m2 by means of disposable elastomeric pumps until progression or toxicity. The median age was 54 years (range, 28-71) and median performance status was 1 (range, 0-3). All patients but four were pretreated with anthracycline- containing regimens or taxanes; the median number of chemotherapy lines was 3 (range, 2-4). Metastatic sites were predominantly visceral in 60% of the patient population. Results: All 30 patients were evaluable for response and toxicity. The median duration of PCI was 20 weeks (range, 2-36 weeks). Two complete responses (7%) and eight partial remissions (26%) were observed, giving an overall response rate of 33%. The median duration of response was six months (range, 4-9 months). Stabilization was observed in seven patients (23%) with a median duration of seven months (range, 3-9 months). The main toxic effects were grade I-II mucositis and hematologic toxicity, while grade 3 hand-foot syndrome was observed in eight patients (27%). Conclusions: This study confirms the efficacy and safety of 5-FU at this dosage and schedule in heavily pretreated women with advanced breast cancer. In order to improve on these results further studies are needed in a less advanced stage of the disease and together with other active drugs.

Original languageEnglish
Pages (from-to)42-45
Number of pages4
JournalTumori
Volume86
Issue number1
Publication statusPublished - Jan 2000

Fingerprint

Fluorouracil
Breast Neoplasms
Appointments and Schedules
Hand-Foot Syndrome
Taxoids
Mucositis
Poisons
Anthracyclines
Pharmaceutical Preparations
Safety
Drug Therapy
Population
Neoplasms

Keywords

  • Breast cancer
  • Continuous infusion
  • Fluorouracil

ASJC Scopus subject areas

  • Cancer Research

Cite this

Crivellari, D., Magri, M. D., Buonadonna, A., Lombardi, D., Paolello, C., De Cicco, M., ... Veronesi, A. (2000). Continuous infusion fluorouracil in the management of advanced breast cancer: A phase II study. Tumori, 86(1), 42-45.

Continuous infusion fluorouracil in the management of advanced breast cancer : A phase II study. / Crivellari, Diana; Magri, Maria Donatella; Buonadonna, Angela; Lombardi, Davide; Paolello, Concetta; De Cicco, Marcello; Fantin, Dario; Veronesi, Andrea.

In: Tumori, Vol. 86, No. 1, 01.2000, p. 42-45.

Research output: Contribution to journalArticle

Crivellari, D, Magri, MD, Buonadonna, A, Lombardi, D, Paolello, C, De Cicco, M, Fantin, D & Veronesi, A 2000, 'Continuous infusion fluorouracil in the management of advanced breast cancer: A phase II study', Tumori, vol. 86, no. 1, pp. 42-45.
Crivellari D, Magri MD, Buonadonna A, Lombardi D, Paolello C, De Cicco M et al. Continuous infusion fluorouracil in the management of advanced breast cancer: A phase II study. Tumori. 2000 Jan;86(1):42-45.
Crivellari, Diana ; Magri, Maria Donatella ; Buonadonna, Angela ; Lombardi, Davide ; Paolello, Concetta ; De Cicco, Marcello ; Fantin, Dario ; Veronesi, Andrea. / Continuous infusion fluorouracil in the management of advanced breast cancer : A phase II study. In: Tumori. 2000 ; Vol. 86, No. 1. pp. 42-45.
@article{1054bc5c174c4098b2856f1f37d3dc19,
title = "Continuous infusion fluorouracil in the management of advanced breast cancer: A phase II study",
abstract = "Aims and background: The evaluation of unconventional schedules of well- known drugs represents a promising avenue in the search for new regimens with a better therapeutic index in metastatic breast cancer. In particular, protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has yielded interesting results in gastrointestinal malignancies and in breast cancer. Methods: From March 1996 30 consecutive patients with heavily pretreated breast cancer were treated with PCI 5-FU at a daily dose of 250 mg/m2 by means of disposable elastomeric pumps until progression or toxicity. The median age was 54 years (range, 28-71) and median performance status was 1 (range, 0-3). All patients but four were pretreated with anthracycline- containing regimens or taxanes; the median number of chemotherapy lines was 3 (range, 2-4). Metastatic sites were predominantly visceral in 60{\%} of the patient population. Results: All 30 patients were evaluable for response and toxicity. The median duration of PCI was 20 weeks (range, 2-36 weeks). Two complete responses (7{\%}) and eight partial remissions (26{\%}) were observed, giving an overall response rate of 33{\%}. The median duration of response was six months (range, 4-9 months). Stabilization was observed in seven patients (23{\%}) with a median duration of seven months (range, 3-9 months). The main toxic effects were grade I-II mucositis and hematologic toxicity, while grade 3 hand-foot syndrome was observed in eight patients (27{\%}). Conclusions: This study confirms the efficacy and safety of 5-FU at this dosage and schedule in heavily pretreated women with advanced breast cancer. In order to improve on these results further studies are needed in a less advanced stage of the disease and together with other active drugs.",
keywords = "Breast cancer, Continuous infusion, Fluorouracil",
author = "Diana Crivellari and Magri, {Maria Donatella} and Angela Buonadonna and Davide Lombardi and Concetta Paolello and {De Cicco}, Marcello and Dario Fantin and Andrea Veronesi",
year = "2000",
month = "1",
language = "English",
volume = "86",
pages = "42--45",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Continuous infusion fluorouracil in the management of advanced breast cancer

T2 - A phase II study

AU - Crivellari, Diana

AU - Magri, Maria Donatella

AU - Buonadonna, Angela

AU - Lombardi, Davide

AU - Paolello, Concetta

AU - De Cicco, Marcello

AU - Fantin, Dario

AU - Veronesi, Andrea

PY - 2000/1

Y1 - 2000/1

N2 - Aims and background: The evaluation of unconventional schedules of well- known drugs represents a promising avenue in the search for new regimens with a better therapeutic index in metastatic breast cancer. In particular, protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has yielded interesting results in gastrointestinal malignancies and in breast cancer. Methods: From March 1996 30 consecutive patients with heavily pretreated breast cancer were treated with PCI 5-FU at a daily dose of 250 mg/m2 by means of disposable elastomeric pumps until progression or toxicity. The median age was 54 years (range, 28-71) and median performance status was 1 (range, 0-3). All patients but four were pretreated with anthracycline- containing regimens or taxanes; the median number of chemotherapy lines was 3 (range, 2-4). Metastatic sites were predominantly visceral in 60% of the patient population. Results: All 30 patients were evaluable for response and toxicity. The median duration of PCI was 20 weeks (range, 2-36 weeks). Two complete responses (7%) and eight partial remissions (26%) were observed, giving an overall response rate of 33%. The median duration of response was six months (range, 4-9 months). Stabilization was observed in seven patients (23%) with a median duration of seven months (range, 3-9 months). The main toxic effects were grade I-II mucositis and hematologic toxicity, while grade 3 hand-foot syndrome was observed in eight patients (27%). Conclusions: This study confirms the efficacy and safety of 5-FU at this dosage and schedule in heavily pretreated women with advanced breast cancer. In order to improve on these results further studies are needed in a less advanced stage of the disease and together with other active drugs.

AB - Aims and background: The evaluation of unconventional schedules of well- known drugs represents a promising avenue in the search for new regimens with a better therapeutic index in metastatic breast cancer. In particular, protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has yielded interesting results in gastrointestinal malignancies and in breast cancer. Methods: From March 1996 30 consecutive patients with heavily pretreated breast cancer were treated with PCI 5-FU at a daily dose of 250 mg/m2 by means of disposable elastomeric pumps until progression or toxicity. The median age was 54 years (range, 28-71) and median performance status was 1 (range, 0-3). All patients but four were pretreated with anthracycline- containing regimens or taxanes; the median number of chemotherapy lines was 3 (range, 2-4). Metastatic sites were predominantly visceral in 60% of the patient population. Results: All 30 patients were evaluable for response and toxicity. The median duration of PCI was 20 weeks (range, 2-36 weeks). Two complete responses (7%) and eight partial remissions (26%) were observed, giving an overall response rate of 33%. The median duration of response was six months (range, 4-9 months). Stabilization was observed in seven patients (23%) with a median duration of seven months (range, 3-9 months). The main toxic effects were grade I-II mucositis and hematologic toxicity, while grade 3 hand-foot syndrome was observed in eight patients (27%). Conclusions: This study confirms the efficacy and safety of 5-FU at this dosage and schedule in heavily pretreated women with advanced breast cancer. In order to improve on these results further studies are needed in a less advanced stage of the disease and together with other active drugs.

KW - Breast cancer

KW - Continuous infusion

KW - Fluorouracil

UR - http://www.scopus.com/inward/record.url?scp=0034026387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034026387&partnerID=8YFLogxK

M3 - Article

C2 - 10778765

AN - SCOPUS:0034026387

VL - 86

SP - 42

EP - 45

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -